Breast cancer as a systemic disease: a view of metastasis

Breast cancer is now the most frequently diagnosed cancer and leading cause of cancer death in women worldwide. Strategies targeting the primary tumour have markedly improved, but systemic treatments to prevent metastasis are less effective; metastatic disease remains the underlying cause of death in the majority of patients with breast cancer who succumb to their disease. The long latency period between initial treatment and eventual recurrence in some patients suggests that a tumour may both alter and respond to the host systemic environment to facilitate and sustain disease progression. Results from studies in animal models suggest that specific subtypes of breast cancer may direct metastasis through recruitment and activation of haematopoietic cells. In this review, we focus on data implicating breast cancer as a systemic disease.

[1]  R. Demicheli,et al.  Recurrence dynamics does not depend on the recurrence site , 2008, Breast Cancer Research.

[2]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[4]  E. Yagüe,et al.  Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients , 2012, British Journal of Cancer.

[5]  G. Semenza,et al.  Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.

[6]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[7]  W. Willett,et al.  Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Jukkola-Vuorinen,et al.  Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[9]  J. O’Shaughnessy Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[10]  H. Kuerer,et al.  Invasive lobular carcinoma predicts micrometastasis in breast cancer. , 2012, The Journal of surgical research.

[11]  Xin Chen,et al.  Granulin–Epithelin Precursor Overexpression Promotes Growth and Invasion of Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[12]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[13]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[14]  S. Aparicio,et al.  Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. , 2012, The oncologist.

[15]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[16]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[17]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[18]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[19]  Erin M. Olson,et al.  Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. , 2013, Breast.

[20]  S. Bicciato,et al.  SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors , 2012, Nature.

[21]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[22]  R. Weinberg,et al.  Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. , 2007, Cancer research.

[23]  P. V. van Diest,et al.  Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases , 2012, Cancer.

[24]  Michael P. Messenger,et al.  Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma , 2012, British Journal of Cancer.

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Friese,et al.  Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients , 2012, Archives of Gynecology and Obstetrics.

[27]  P. Carmeliet,et al.  Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? , 2011, Nature Reviews Clinical Oncology.

[28]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[29]  Gyan Bhanot,et al.  Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.

[30]  R. Dienstmann,et al.  Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer , 2012, Drug Safety.

[31]  Circulating Tumor Cells as Predictors of Response and Failure in Breast Cancer Patients Treated with Preoperative Chemotherapy , 2013, The International journal of biological markers.

[32]  Lodewyk F. A. Wessels,et al.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response , 2009, Breast Cancer Research and Treatment.

[33]  S. Kurtz,et al.  Quantitative High-Resolution Genomic Analysis of Single Cancer Cells , 2011, PloS one.

[34]  K. Pantel,et al.  Molecular mechanisms of metastasis , 2011, Journal of surgical oncology.

[35]  E. Scarpi,et al.  Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. , 2012, Clinical breast cancer.

[36]  R. Supramaniam New malignancies among cancer survivors: SEER cancer registries, 1973–2000 , 2008, Journal of Epidemiology & Community Health.

[37]  C. Ménard,et al.  Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response , 2012, British Journal of Cancer.

[38]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[39]  Vandana Iyer,et al.  Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. , 2012, Cancer research.

[40]  G. Breier,et al.  Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients. , 2012, Clinical laboratory.

[41]  Chih‐Ping Han,et al.  Detection of minimal residual disease in blood and bone marrow in early stage breast cancer , 2011, Cancer.

[42]  A. Richardson,et al.  Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. , 2012, Cancer discovery.

[43]  I. Martinez-Zubiaurre,et al.  Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. , 2012, Experimental and therapeutic medicine.

[44]  P. Fasching,et al.  Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study , 2012, Breast Cancer Research.

[45]  D. Wallwiener,et al.  Results of iliac crest biopsies taken from 1465 patients with primary breast cancer , 1998, Journal of Cancer Research and Clinical Oncology.

[46]  N. Almog Molecular mechanisms underlying tumor dormancy. , 2010, Cancer letters.

[47]  C. Pugh,et al.  Hypoxia and oxidative stress in breast cancer: Hypoxia signalling pathways , 2001, Breast Cancer Research.

[48]  J. Thiery,et al.  Complex networks orchestrate epithelial–mesenchymal transitions , 2006, Nature Reviews Molecular Cell Biology.

[49]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[50]  Gerhard Christofori,et al.  Molecular networks that regulate cancer metastasis. , 2012, Seminars in cancer biology.

[51]  X. Zha,et al.  The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform , 2012, British Journal of Cancer.

[52]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Debra L Winkeljohn Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[54]  D. Genovesi,et al.  Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[55]  A. Chambers,et al.  Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management , 2007, Journal of cellular biochemistry.

[56]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[57]  B. Xu,et al.  Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  A. Bateman,et al.  The granulin gene family: from cancer to dementia , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[59]  P. Lønning,et al.  Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival , 2012, Breast Cancer Research.

[60]  Tao Wang,et al.  Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer , 2012, Clinical Cancer Research.

[61]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[62]  R. Walker,et al.  The complexities of breast cancer desmoplasia , 2001, Breast Cancer Research.

[63]  J. Sachdev,et al.  Evolution of bevacizumab-based therapy in the management of breast cancer. , 2008, Clinical breast cancer.

[64]  Ahmedin Jemal,et al.  Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[65]  L. Livi,et al.  Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience , 2013, Medical Oncology.

[66]  J. Cuzick,et al.  Aspirin and cancer risk: a quantitative review to 2011. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  A. Goldhirsch,et al.  Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. , 2012, Clinical breast cancer.

[68]  Kshitiz,et al.  Erratum: Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis (Journal of Clinical Investigation (2013) 123: 1 (189-205) DOI: 10.1172/JCI64993) , 2013 .

[69]  G. Semenza,et al.  Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer , 2012, PloS one.

[70]  R. Hoover,et al.  New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. , 2006 .

[71]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[72]  R. Demicheli,et al.  Recurrence and mortality according to Estrogen Receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast , 2010, BMC Cancer.

[73]  P. Goss,et al.  Putative growth characteristics of micrometastatic breast cancer , 2008, Breast Cancer Research.

[74]  Jay W. Shin,et al.  Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor , 2012, International journal of oncology.

[75]  A. Levchenko,et al.  Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. , 2012, The Journal of clinical investigation.

[76]  T. Fehm,et al.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients , 2008, Breast Cancer Research.

[77]  L. Harris,et al.  Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer , 2012, Breast Cancer Research and Treatment.

[78]  Anne E Carpenter,et al.  Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. , 2011, The Journal of clinical investigation.

[79]  G. Lorusso,et al.  New insights into the mechanisms of organ-specific breast cancer metastasis. , 2012, Seminars in cancer biology.

[80]  J. Folkman Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.

[81]  E. Kraynov,et al.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer , 2012, Journal of Experimental & Clinical Cancer Research.

[82]  J. Reuben,et al.  Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome , 2012, BMC Cancer.

[83]  J. Folkman,et al.  Tumor dormancy due to failure of angiogenesis: role of the microenvironment , 2008, Clinical & Experimental Metastasis.

[84]  King-Jen Chang,et al.  Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.

[85]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.